Loma Therapeutics joins BioInnovation Institute’s (BII) Venture Lab program with a mission to revolutionize HPV cancer treatment and to address the pressing global health crisis posed by HPV-related cancers. Participation in BII’s Venture Lab program provides...
Human ex vivo validation of the potential of Loma’s HPV-targeted immunotherapy has been published in Cancers. The study conducted in collaboration between Loma Therapeutics and Hervolution supports that Loma’s unique immunotherapy can induce strong and functional CD8+...
Loma Therapeutics was awarded for Merck’s Advance Biotech Grant for their pitch at the Nordic Stars Pitch Competition. CEO Ditte Boilesen and COO Stephanie Holstein-Rønsbo received the award on stage, which includes bioprocessing technologies and services valued at...